# Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

> **NCT02576093** · PHASE1 · COMPLETED · sponsor: **Dr. August Wolff GmbH & Co. KG Arzneimittel** · enrollment: 58 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** 0.1% WOL071-007
- **DRUG:** 0.3% WOL071-007
- **DRUG:** 1.0% WOL071-007
- **DRUG:** Placebo of WOL071-007

## Key facts

- **NCT ID:** NCT02576093
- **Lead sponsor:** Dr. August Wolff GmbH & Co. KG Arzneimittel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2015-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576093, "Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02576093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*